MétaCan
Menu
Back to cohort
Record W4322758628 · doi:10.1007/s00702-023-02609-6

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study

2023· article· en· W4322758628 on OpenAlexaboutno aff
Fabien Zagnoli, A. Leblanc, Irina Viakhireva-Dovganyuk, Jean-Philippe Delabrousse-Mayoux, Alain Pouyet, Marc Ziégler, Laura Sogni, Marie Patat, Régis Bouillot, Marc Vérin, Andrei Arhire, P Barres, Maxime Blondiaux, Jean-Claude Bouffeteau, Jean‐Philippe Brandel, Christophe Carel, Giovanni Castelnovo, Marc Coustans, Lucie Courault, Christian Crauser, Isabelle Degaey, Bertrand Degos, Jean-Philippe Delabrousse, Béatrice Denis, Marie-Claude Dourneau, Arnaud Duretete, Jean-Marc François Feve, Erika Follin, Michel Gugenheim, C. Hubsch, Nathalie Patte Karsenti, Pierre Louchart, Serge Massengo, José Mejías, Homero Monteiro, Philippe Muh, Bernard Pedespan, Virginie Sattler, M. Sévin, Mélissa Tir, Anne Tirel Badets, Irina Viakhireva, Elisabeth Vidry, Jean-Charles Wiart

Bibliographic record

VenueJournal of Neural Transmission · 2023
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineParkinson's diseaseObservational studyApomorphineQuality of life (healthcare)Adverse effectRating scaleClinical Global ImpressionPhysical therapyDiseaseAmbulatoryPsychologyInternal medicineAlternative medicineDopamineDopaminergicNursing

Abstract

fetched live from OpenAlex

Continuous subcutaneous apomorphine infusion (CSAI) is used to treat patients with Parkinson's disease (PD) who are experiencing motor fluctuations. However, the need to initiate this treatment during a hospital stay may restrict patients' access to it. To assess the feasibility and benefits of initiating CSAI in the patient's own home. A French prospective multicenter longitudinal observational study (APOKADO) among patients with PD who required subcutaneous apomorphine, comparing in-hospital versus home initiation. Clinical status was assessed according to the Hoehn and Yahr score), the Unified Parkinson's Disease Rating Scale Part III, and the Montreal Cognitive Assessment. We assessed patients' quality of life with the 8-item Parkinson's Disease Questionnaire, rated the improvement in their clinical status on the 7-point Clinical Global Impression-Improvement scale, recorded adverse events, and ran a cost-benefit analysis. 145 patients with motor fluctuations were included in 29 centers (office and hospital). Of these, 106 (74%) were initiated onto CSAI at home, and 38 (26%) in hospital. At inclusion, the two groups were comparable for all demographic and PD characteristics. After 6 months, quality of life, adverse events and early dropout rates were similarly rare-across the two groups. Patients in the home group improved more quickly their quality of life and became more autonomous in managing the device than those in the hospital group, and their care costed less. This study shows that home (versus in-hospital) initiation of CSAI is feasible, improves patients' quality of life more quickly, with the same level of tolerance. It is also less expensive. This finding should make it easier for patients to access this treatment in the future.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.048
Threshold uncertainty score0.282

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.281
Teacher spread0.244 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations22
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Neural TransmissionSame topicParkinson's Disease Mechanisms and TreatmentsFrench-language works237,207